title: [Clinical efficacy of high-dose cepharanthine for idiopathic thrombocytopenic purpura: retrospective multicenter analysis].
abstract: Cepharanthine (CEP), an alkaloid drug that has a cell membrane stabilizing effect and an immunomodulating effect, has been reported to improve symptoms and signs of chronic immune thrombocytopenia (ITP). In this study, we retrospectively assessed the clinical efficacy and adverse events of high-dose CEP for 47 patients with ITP. The response rate (elevation of platelet count>5×10(4)/μl) was 44%, and CEP treatment was judged useful in clinical aspects by their attending doctors in 77% of the cases. Next, we made a comparative analysis between patients who were administered CEP as a single agent (22 patients) and those administered CEP in combination therapy with prednisolone (PSL) (20 patients). There was a marked increase in platelet count in both groups compared to the count before CEP treatment (P<0.01), and no significant difference was seen between the two groups. High-dose CEP was well tolerated, and in some patients single-agent CEP therapy resulted in a significant elevation of platelets, allowing a reduced dosage of PSL.
authors: Department of Hematology, Hokkaido University Hospital, Japan.
authors: Mutsumi
authors: M
authors: Takahata
authors: Satoshi
authors: S
authors: Hashino
authors: Katsuya
authors: K
authors: Fujimoto
authors: Tomoyuki
authors: T
authors: Endo
authors: Naoki
authors: N
authors: Kobayashi
authors: Mitsutoshi
authors: M
authors: Kurosawa
authors: Hiroshi
authors: H
authors: Iwasaki
authors: Takayoshi
authors: T
authors: Miyake
authors: Kyuhei
authors: K
authors: Kohda
authors: Isao
authors: I
authors: Maekawa
authors: Hiroshi
authors: H
authors: Sasagawa
authors: Yutaka
authors: Y
authors: Tsustumi
authors: Takuto
authors: T
authors: Miyagishima
authors: Junji
authors: J
authors: Tanaka
authors: Masahiro
authors: M
authors: Imamura
authors: Takanori
authors: T
authors: Teshima
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044182:Benzylisoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010976:Platelet Count / Q000379:methods; D011239:Prednisolone / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult; D052117:Benzodioxoles
chemical_list: D044182:Benzylisoquinolines; D011239:Prednisolone; C006947:cepharanthine; D052117:Benzodioxoles